Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MMSC in Parkinson's Disease
NCT04146519Phase 3Unknown
- Sponsor
- Belarusian Medical Academy of Postgraduate Education
- Start
- Jul 2017
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of autologous mesenchymal stem cells in Parkinson's disease (PD) (2 arms), sponsored by Belarusian Medical Academy of Postgraduate Education. Primary endpoints: Motor symptoms change at 3 months, Non-motor symptoms change at 3 months and 3 more. Status: unknown.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04146519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146519.